Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients
Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients
复制标题
可溶性PD-L1是阻塞性睡眠呼吸暂停患者皮肤黑色素瘤侵袭和转移的潜在生物标志物
DOI：
10.1183/13993003.01298-2018
复制
发表时间：
2019-02-01
影响因子：
24.3
通讯作者：
Garcia-Rio, Francisco
中科院分区：
文献类型：
--
作者：
Cubillos-Zapata, Carolina;Angel Martinez-Garcia, Miguel;Garcia-Rio, Francisco
阻塞性睡眠呼吸暂停（OSA）上调程序性细胞死亡-1受体及其配体（PD-L1）通路，可能损害免疫监视。我们根据OSA的存在和严重程度比较了皮肤黑色素瘤患者循环中可溶性PD-L1（sPD-L1）的水平，并评估了与肿瘤侵袭性和侵袭性的关系。在一项多中心观察性研究中，360例皮肤黑色素瘤患者接受了睡眠研究，血清sPD-L1水平采用ELISA法测定。皮肤黑色素瘤侵袭性指标包括有丝分裂率、Breslow指数、肿瘤溃疡、Clark水平和肿瘤分期，并记录前哨淋巴结（SLN）转移作为侵袭性的标志物。重度OSA患者sPD-L1水平高于轻度OSA或非OSA患者。在OSA患者中，sPD-L1水平与Breslow指数相关，并且在肿瘤溃疡、晚期原发肿瘤或局部疾病患者中更高。将sPD-L1与SLN转移的经典危险因素相结合，可使SLN转移的分类净改善27.3%，因此sPD-L1水平在重度OSA患者中升高，并可能作为这组受试者皮肤黑色素瘤侵袭性和侵袭性的潜在生物标志物。
Obstructive sleep apnoea (OSA) upregulates the programmed cell death-1 receptor and its ligand (PD-L1) pathway, potentially compromising immunosurveillance. We compared circulating levels of soluble PD-L1 (sPD-L1) in patients with cutaneous melanoma according to the presence and severity of OSA, and evaluated relationships with tumour aggressiveness and invasiveness.In a multicentre observational study, 360 patients with cutaneous melanoma underwent sleep studies, and serum sPD-L1 levels were assayed using ELISA. Cutaneous melanoma aggressiveness indices included mitotic rate, Breslow index, tumour ulceration, Clark level and tumour stage, and sentinel lymph node (SLN) metastasis was recorded as a marker of invasiveness.sPD-L1 levels were higher in severe OSA compared to mild OSA or non-OSA patients. In OSA patients, sPD-L1 levels correlated with Breslow index and were higher in patients with tumour ulceration, advanced primary tumour stages or with locoregional disease. The incorporation of sPD-L1 to the classic risk factors to SLN metastasis led to net improvements in the classification of 27.3%.Thus, sPD-L1 levels are increased in melanoma patients with severe OSA, and, in addition, might serve as a potential biomarker of cutaneous melanoma aggressiveness and invasiveness in this group of subjects.